WuXi Biologics

WuXi Biologics (Stock Code: 2269.HK) is a world-leading Contract Research, Development and Manufacturing Organization (CRDMO). Through an open-access, integrated biologics capability and technology empowerment platform, the company provides end-to-end services to help partners discover, develop, and manufacture biologics, covering the entire process from concept to commercial production. This accelerates the global biologics R&D process, reduces R&D costs, and benefits patients. WuXi Biologics has over 12,000 employees in China, the United States, Ireland, Germany, Singapore, and Qatar. Leveraging its professional service team, advanced technology, and deep insights, the company delivers efficient and cost-effective biologics solutions to its clients. As of December 31, 2025, WuXi Biologics has supported a total of 945 integrated projects for clients, including 74 Phase III clinical projects and 25 commercial production projects. WuXi Biologics regards Environmental, Social, and Governance (ESG) as a key component of its business development and corporate spirit, striving to become an ESG leader in the global biologics CRDMO sector by adopting greener next-generation biopharmaceutical technologies and energy sources to drive industry progress. The company has established an ESG Committee led by the CEO to fully implement its ESG strategy and fulfill its commitment to sustainable development.